Non-Invasive Monitoring • REVEAL Lite 2
Awaiting Follow-up Data
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
Follow-up Monitoring
Routine follow-up of patients with established WHO Group 1 PAH.
Monitoring treatment response without invasive hemodynamics (RHC).
Risk assessment at quarterly or bi-annual intervals.
When to Use
REVEAL Lite 2 is intended for follow-up assessments. Baseline risk stratification should ideally use the full 13-variable REVEAL 2.0 score incorporating Right Heart Catheterization.
How it Works
The 6 Non-Invasive Variables
| Variable | Criteria | Points |
|---|---|---|
| NYHA/WHO FC | Class III / Class IV | +1 / +2 |
| SBP | < 110 mmHg | +1 |
| Heart Rate | > 96 bpm | +1 |
| 6MWD | < 165 m | +1 |
| BNP / NT-proBNP | BNP 200–799 / ≥ 800 | +1 / +2 |
| Renal Function | eGFR < 60 mL/min/1.73m² | +1 |
Scoring Thresholds
| Low Risk | Score ≤ 5 |
| Intermediate Risk | Score 6–7 |
| High Risk | Score ≥ 8 |
Clinical Pearls
Validation Data
REVEAL Lite 2 has a C-statistic of 0.70. While slightly lower than the full 2.0 version (0.76), it provides reliable risk categorization purely through bedside assessment and standard labs.
The Evidence
Primary Source
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2.
Benza RL et al. • Chest. 2021;
Last Comprehensive Review: 2026-07-17